• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Baxter BioPharma Solutions

    Emergent BioSolutions

    Aphena Pharma Solutions

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    test company saurabh

    Reed-Lane

    Emergent BioSolutions

    Baxter BioPharma Solutions

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    FDA & Data Integrity

    FDA Publishes Final Guidance on Data Integrity

    FDA & Data Integrity
    Related CONTENT
    • Mogene
    • Vetio Animal Health
    • Contracting And Outsourcing Exhibitor List
    • Do You Have Weaknesses? Of Course I Do!
    • FDA Approves MabPlex's IND
    Robert Marohn, Director of Quality Business Systems, Kite Pharmaceutical01.25.19
    On December 13, 2018 the U.S. Food and Drug Administration (FDA) released the final version of its guidance titled, “Data Integrity and Compliance with Drug CGMP: Questions and Answer.”1 The guidance is preceded by a statement released a day earlier from FDA Commissioner Scott Gottlieb, M.D., on “…the agency’s efforts to improve drug quality through data integrity and good manufacturing practice oversight.”2
    The guidance and statement place an exclamation point on FDA’s focus on “ensuring data associated with drug manufacturing are complete, consistent, and accurate, and therefore reliable,” as emphasized by Commissioner Gottlieb. This article looks at the important elements of FDA’s final data integrity guidance, its impact to contract pharmaceutical organizations, and notable updates from FDA’s draft version of the guidance.

    While FDA expects all data to be reliable and accurate, the introduction of the final guidance emphasizes that firms should “implement meaningful and effective strategies to manage their data integrity risks based on their process understanding and knowledge management of technologies and business models.” For more information on risk assessment and analysis, see Contract Pharma’s September 2017 feature, “Data Integrity: A Practical and Risk-Based Approach.”3

    Guidance Background
    Dr. Gottlieb noted, “Over the past decade, we’ve [FDA] uncovered situations in which drug quality data and information are not accurate.” Indeed, trends show an increase of data integrity sightings by the FDA since 2008. Recently, the number of data integrity associated Warning Letters have been dramatically increasing with 15 (0 U.S.) in 2015, 41 (7 U.S.) in 2016, 56 (19 U.S.) in 2017.4 Most often such data integrity observations result from inadequate processes and systems to ensure reliable and accurate data, which in all cases, FDA regards as a risk to patient safety.

    As in the draft guidance, the background section of the final guidance clearly states that requirements with respect to data integrity already exist in 21 CFR parts 211, 212; as well as 21 CFR part 11 and goes on to list each part as it relates to data integrity. The message is clear that expectations of data integrity have long existed in predicate rules, and therefore companies are assumed to meet such requirements when complying with respective rules today.

    New in the background section of the final guidance, FDA says when considering how to meet many regulatory requirements related to data integrity, it may be useful to ask a series of questions. Data integrity stewards in organizations will want to carefully consider these questions to ensure they meet data integrity requirements. 2018 Warning Letter violations show a continued trend of infringements involving data integrity during CGMP inspections. A review of causes for these warnings found examples of 2018 data integrity violations related to each of the seven questions FDA states companies should consider (see Table 1 below).

    Guidance Q&As
    The bulk of the final guidance covers 18 questions and answers about data integrity that highlight the most important ideas the agency expects firms to understand. The concepts cover the design, operation, and monitoring of systems and controls to maintain data integrity. It clarifies key terms, including the definition of data integrity and ALCOA,6 while placing an emphasis on all aspects of data governance throughout the data life cycle. The final guidance states, “System design and controls should simplify the detection of errors, omissions and aberrant results throughout the data’s life cycle.”

    All the Q&As in this final guidance should be reviewed by contract pharmaceutical organizations to ensure they are adopting these principals in their data integrity programs. However, some notable Q&As for the contract pharmaceutical industry to consider in this final guidance include the following:

    • In Q&A #7 on “Who should review audit trails?” the guidance states, “…all production and control records, which includes audit trails, must be reviewed and approved by the quality unit.” And contract pharmaceutical firms will want to pay attention to FDA’s recommendation to “use a quality system approach to implementing oversight and review of CGMP records.” Specifically, FDA footnoted its guidance on Quality Systems Approach to Pharmaceutical CGMP Regulations. And for information about auditing as it relates to contract facilities, it footnoted its guidance on Contract Manufacturing Arrangements for Drugs: Quality Agreements. Related, see Contract Pharma June 2018 column, “Putting Data Integrity in Quality Agreements.”7

    • In Q&A #13 on “Why has FDA cited use of actual samples during ‘system suitability’ or test, prep, or equilibration runs in warning letters?” the FDA addresses the issue of “testing into compliance.” Contract manufacturers will want to remember, FDA states using a strategy of repeated testing until a passing result is obtained, then disregarding the out of specification results without scientific justification is unscientific and unacceptable under CGMPs.8 In addition, data integrity best practices require the complete life cycle of CGMP data be preserved.

    • In Q&A #14 on “Is it acceptable to only save the final results from reprocessed laboratory chromatography?” FDA says no, and emphasizes the data integrity concept of completeness. Again, the complete life cycle of CGMP data must be protected and maintained. FDA expects that aborted or incomplete results must be captured in an audit trail and also investigated and justified.

    Notable Updates from FDA Draft Data Integrity Guidance
    The final guidance, for the most part, aligns with the draft guidance released in April 2016. However, there are four modifications that standout in the final guidance: management involvement, restrictive access controls, enhanced audit trail reviews, and handling of invalidated data.

    FDA adds to the final guidance emphasis on the role of management to create a quality culture in the organization. Management should ensure employees understand that data integrity is an organizational core value and be encouraged to identify and promptly report data integrity issues.

    In the draft guidance, the FDA recognized that some manufacturers may be too small to have independent security role assignments. The final guidance does not, and emphasizes the importance of separating responsibilities related to administration from record content production accounts.

    Also, the final guidance clarifies when audit trails should be reviewed based on frequency and/or risk. If the timing for data reviews is already explicitly stated in a CGMP regulation, the frequency of audit trail review should match this timing. However, where not called out, a risk based approach may be used, taking into account the critical nature of the data and its impact on product quality. The guidance provides examples that give direction on this topic.

    Finally, the draft guidance did not spell out that invalidated data must be evaluated by the quality unit pursuant to release. However, the final guidance is clear; such data is within the scope of the quality unit’s batch record review before release.

    Conclusion
    In 2018 the Medicines and Healthcare products Regulatory Agency (MHRA) (see, “New GXP Data Integrity Guidance Published by MHRA,” in the April 2018 edition of Contract Pharma9) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) also finalized their draft guidance on data integrity, rounding out a year when we saw all of these organizations, along with the FDA, settle their thinking on the topic. FDA Commissioner Gottlieb states, “As the industry has globalized, we’ve expanded our partnerships with our international regulatory counterparts.”

    Expect regulatory agencies to exchange information about quality and data integrity related violations observed in facilities around the world. Expect these agencies to work together to advance best practices to help pharmaceutical companies improve their compliance with data integrity regulations as a key step to ensure the safety, efficacy, and quality of drugs. 


     


    References
    1. www.fda.gov/downloads/drugs/guidances/ucm495891.pdf
    2. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm628244.htm
    3. www.contractpharma.com/issues/2017-09-01/view_features/data-integrity-a-practical-and-risk-based-approach
    4. www.pharmaceuticalonline.com/doc/an-analysis-of-fda-warning-letters-on-data-integrity-0003
    5. www.fda.gov/ICECI/EnforcementActions/WarningLetters/2018/default.htm
    6. Complete, consistent, and accurate data should be attributable, legible,contemporaneously recorded, original or a true copy, and accurate (ALCOA).
    7. www.contractpharma.com/issues/2018-06-01/view_columns/putting-data-integrity-in-quality-agreements/45262
    8. www.fda.gov/downloads/drugs/guidances/ucm070287.pdf
    9. www.contractpharma.com/issues/2018-04-01/view_columns/new-gxp-data-integrity-guidance-published-by-mhra/49675



     
    Robert Marohn is the Director of Quality Business Systems at Kite Pharmaceutical, a Gilead company. He has worked in the life science industry for over twenty years. Previously, he served as the Chief Information Officer of Worldwide Clinical Trials for eight years. He holds a Master of Science in the Management of Technology from Georgia Institute of Technology and is currently pursuing a Ph.D. in Information Systems and Technology at Claremont Graduate University.
    Related Searches
    • cGMP
    • fda
    • www.contractpharma.com
    • contractpharma.com
    Suggested For You
    Mogene Mogene
    Vetio Animal Health Vetio Animal Health
    Contracting And Outsourcing Exhibitor List Contracting And Outsourcing Exhibitor List
    Do You Have Weaknesses? Of Course I Do! Do You Have Weaknesses? Of Course I Do!
    FDA Approves MabPlex FDA Approves MabPlex's IND
    Recro Pharma Amends IV Meloxicam License Agreement with Alkermes Recro Pharma Amends IV Meloxicam License Agreement with Alkermes
    FDA Grants Mustang Bio ODD FDA Grants Mustang Bio ODD
    Serialization Implementation Serialization Implementation
     Dedicated to Excellence Dedicated to Excellence
    Pharma Future: Trends to Watch Pharma Future: Trends to Watch
    Anti-Cancer Evaluations with ICH S9 Guideline: What you need to know Anti-Cancer Evaluations with ICH S9 Guideline: What you need to know
    FDA Grants Albireo Pharma ODD FDA Grants Albireo Pharma ODD
    CPL Details Full-Service Offerings CPL Details Full-Service Offerings
    Reporting CPPs to FDA Reporting CPPs to FDA
    Renaissance Pharma at Contracting & Outsourcing 2018 Renaissance Pharma at Contracting & Outsourcing 2018

    Related Features

    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • Information Technology
      You Need Solutions, Digitization is the Answer

      You Need Solutions, Digitization is the Answer

      Cloud technology helps today’s contract manufacturers be agile, transparent and efficient.
      Brian Curran, Senior Vice President of Strategic Growth, MasterControl 10.14.20

    • Information Technology
      Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

      Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

      The proven promise and huge potential of using AI and ML to accelerate drug discovery.
      Lucas Glass, Gary Shorter, and Rajneesh Patil, IQVIA 11.20.19

    • Information Technology
      A Brave New World of Data Integrity

      A Brave New World of Data Integrity

      How modern CMOs are keeping up with stringent regulatory guidelines by embracing advanced laboratory information systems.
      Bob Voelkner, VP Sales and Marketing, LabVantage 06.13.19


    • Clinical Trials | Information Technology
      The New Horizon: Metaprise Analytics in Life Sciences

      The New Horizon: Metaprise Analytics in Life Sciences

      Going beyond enterprise analytics to metaprise analytics—patient-centric systems that create a data driven trial team.
      Michelle Longmire, MD, CEO and Founder, Medable 05.07.19

    • Information Technology
      The Manufacturing Revolution In Medicine

      The Manufacturing Revolution In Medicine

      Real-time data insights help both pharma companies and contract manufacturers meet regulatory requirements while ensuring high production standards.
      Petter Moree, OSIsoft, LLC 05.07.19

    • Information Technology
      Industry 4.0 in the Pharma Industry

      Industry 4.0 in the Pharma Industry

      Digitization is not a single-handed project.
      Dr. Christian Hanisch, Project Manager Industry 4.0 Pharma, Bosch Packaging Technology 03.06.19


    • Information Technology
      Digitization: Pharma 4.0

      Digitization: Pharma 4.0

      A look at how technology is impacting the pharma industry
      Fatih Kaya and Gerald Buerkle, Vetter Pharma 01.25.19

    • Information Technology | Serialization | Supply Chain
      Serialization Compliance

      Serialization Compliance

      Automated data controls during packaging help improve compliance.
      Miguel Pitarch, Executive Director, Global Serialization, Bristol-Myers Squibb & the Bristol-Myers Squibb Serialization Team 11.13.18

    • Clinical Trial Materials | Information Technology
      Interactive Response Technology in Clinical Trial Supply

      Interactive Response Technology in Clinical Trial Supply

      Exploring the benefits of including IRT professionals earlier in trial planning
      Dave Holly, Senior Manager, IRT Development and Operations, Sharp Clinical Services 10.10.18


    • Drug Development | Information Technology | R&D
      CRO Industry Update: Big Data Drives Drug Development Efforts

      CRO Industry Update: Big Data Drives Drug Development Efforts

      With growth in virtual trials and RWE, the clinical development landscape may never look the same
      Kristin Brooks, Managing Editor 05.11.18

    • Information Technology | Serialization
      Stripping Serialization Back to Data Integrity

      Stripping Serialization Back to Data Integrity

      Why companies can’t afford to make compromises on quality
      Rachna Mohanka, Sr. Director, Global Solution Consulting, TraceLink 05.08.18

    • Information Technology | Regulatory Affairs
      Data Integrity: A Practical  and Risk-Based Approach

      Data Integrity: A Practical and Risk-Based Approach

      Ways an organization can form a culture and cost-effective means to meet the various challenges in sustaining data integrity.
      Robert Marohn, ClinLogic, LLC 09.06.17

    Trending
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Spark Therapeutics Appoints CTO
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Catalent Acquires Delphi Genetics
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Cosmetic Chemical Sales To Post CAGR 5.8% To 2025
    ACI Urges Senate to Approve Regan as EPA Administrator
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login